Benefits to patients

• Improved and more timely access to specialised diagnostics, clinics and treatments.
• Coordinated patient pathway for cardiac amyloidosis.
• Improve adherence to medicines through additional clinical fellow specialist support.
• Continuity of care between the tertiary hospital and secondary care hospitals.
• Reduction in number of unnecessary hospital visits.
• Supporting better outcomes for cardiac amyloidosis patients (e.g., improve decision making at specialist MDT, access to expert diagnostics, direct links to the National Amyloidosis Centre (NAC)).
• Timely case review will lead to quicker MDT discussions, faster access to specialist services, and reduced waiting times for diagnostics.
• Reduced variation between Trusts across the network for all CA patients entering the clinical pathway.  

Benefits to the NHS

• Increased cross hospital collaboration.
• Improved clinical pathways.
• Reduced cardiology waiting times.
• Maintain or improve the time from referral to diagnosis of 43 days at LTHT.
• Improved access to diagnostics.
• Reduced duplication of imaging and other diagnostic investigations.
• Improved education on cardiac amyloidosis.
• Clinical care aligned with standards of care developed by the NAC.
• Data collection in line with interventions of Rare Disease Framework and England Action Plan 2022.
• Improved education on cardiac amyloidosis..

Benefits to Pfizer

• The project may result in the identification of patients who are eligible for appropriate treatments prescribed in line with current national and local guidelines (which may include licensed Pfizer medicine).
• Accelerated initiation of appropriate licensed treatments for patients diagnosed with cardiac amyloidosis under the guidance of an expert clinician.
• Increased understanding of service provision and patient pathway design